OncoMatch/Clinical Trials/NCT04511078
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
Is NCT04511078 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Panitumumab-IRDye800 for head and neck cancer.
Treatment: Panitumumab-IRDye800 — The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage ANY T STAGE
Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection
Prior therapy
Cannot have received: investigational drug
Lab requirements
Blood counts
Hemoglobin ≥ 9 gm/dL; Absolute Neutrophil Count ≥ 1500; White Blood Cell count > 3000/mm3; Platelet count ≥ 100,000/mm3
Kidney function
Serum creatinine ≤ 1.5 times upper reference range
Liver function
acceptable liver function
Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; Absolute Neutrophil Count ≥ 1500; White Blood Cell count > 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify